1. Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease
- Author
-
Miriam B. Vos, Lara Dimick-Santos, Ruby Mehta, Stephanie O. Omokaro, Johannes Taminiau, Elmer Schabel, David E. Kleiner, Peter Szitanyi, Piotr Socha, Jeffrey B. Schwimmer, Stephanie Noviello, Debra G. Silberg, Richard Torstenson, Veronica Miller, Joel E. Lavine, Nathalie Adda, William Baldyga, Rajarshi Banerjee, Cynthia Behling, Sherif Boulos, Gary Burgess, Dania Calboli, Edgar Charles, Rose Christian, Claude Cohen-Bacrie, Doina Cosma-Roman, Claus-Peter Danzer, Ingrid Delaet, Mark Delegge, Nicholas DiProspero, Kathleen Donohue, Laurent Fischer, Emer Fitzpatrick, Michael Fried, David Hagerty, Paula Hale, Keri Hildick, Dean Hum, Khurram Jamil, Lijuan Jiang, Saul Karpen, Matt Kelly, Rohit Kohli, Kattayoun Kordy, Nancy Krieger, Joel Lavine, Lois Lee, Eric Lefebvre, Patricia Lopez, Erica Lyons, Laura Malahias, Sophie Megnien, Peter Mesenbrink, Pansy Minnick, Christine Murray, Tien Nghiem, Nikki Nicholson, Wenjie Pang, Lisa Percival, Dan Peres, Margaret Powell, Dragos Roman, Mark Root, Claire Sampson, Arun Sanyal, Kathleen Schwarz, Star Seyedkazemi, David Shapiro, Reshma Shringarpure, Debra Silberg, Edward Smith, Robert Squires, William Treem, Pamela Vig, Miriam Vos, Mason Yamashita, Michael Zemel, and Liver Forum Pediat Working Grp
- Subjects
medicine.medical_specialty ,MEDLINE ,Gastroenterology ,Severity of Illness Index ,Article ,Drug Development ,Non-alcoholic Fatty Liver Disease ,Internal medicine ,Nonalcoholic fatty liver disease ,Severity of illness ,medicine ,Prevalence ,Humans ,Child ,Clinical Trials as Topic ,Hepatology ,business.industry ,Patient Selection ,Age Factors ,medicine.disease ,Drug development ,Liver ,Human medicine ,business ,Liver pathology - Published
- 2019